Mylan Wins Approval of Generic Norvasc

Mylan Laboratories Inc. won U.S. regulatory approval for a generic version of Pfizer Inc.’s blood-pressure pill Norvasc.

The Food and Drug Administration confirmed that Mylan was the first to file for approval of generic Norvasc, giving it six months of marketing exclusivity, the Canonsburg, Pa.- based company said.

The period of protected sales will start when Mylan launches its product or when a patent dispute is resolved.

Pfizer is fighting generic Norvasc plans by Mylan and three other companies.

Mylan shares rose $1.02 to $20.40.